What Inflacam 0.5% Treats: Main Uses and Benefits

The medication is commonly used as a Nonsteroidal Anti-inflammatory Drug (NSAID) to provide supportive symptomatic relief in conditions where pain and inflammation create noticeable physiological strain. The medication is indicated for addressing the signs and symptoms of major chronic and acute inflammatory processes.

Managing Chronic Inflammatory Joint Pain

This medication is utilized for adults coping with conditions characterized by periods of heightened symptoms, such as osteoarthritis and rheumatoid arthritis. It is utilized for the management of persistent discomfort, tenderness, and symptoms that interfere with daily functioning, such as joint stiffness, associated with long-term arthritic diseases. It contributes to improved day-to-day comfort and assists with maintaining functional stability during symptomatic periods. It is used in conditions involving symptomatic relief for examples such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and gouty arthritis.

Assisting with Acute and Episodic Musculoskeletal Discomfort

The medication is also applied across domains where short-term symptomatic assistance is needed, such as in acute musculoskeletal episodes or exacerbations. This includes managing symptoms related to inflammatory or irritative states, such as acute pain and swelling from soft tissue injuries. It may also assist with managing symptoms related to other recurrent or episodic manifestations like primary dysmenorrhoea (menstrual pain), helping to maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. NIH MedlinePlus overview of Piroxicam

Who Can and Cannot Use Inflacam 0.5%?

The population eligibility for Inflacam 0.5% (Piroxicam, an NSAID) is strictly defined by government regulatory documents, focusing on populations for whom use is allowed, restricted, or absolutely prohibited.

Contraindicated Populations (Must Not Use)

Official labeling contraindicates the use of this medicine for specific groups. These include patients with a known hypersensitivity to Piroxicam or other NSAIDs, those with a history of gastrointestinal ulceration, bleeding, or perforation, and individuals with severe heart failure, severe renal impairment, or severe hepatic impairment. Use is also strictly prohibited during the third trimester of pregnancy and in patients recovering from coronary artery bypass graft (CABG) surgery.

Restricted and Non-Recommended Use

The medicine is generally indicated for adults. However, use is not recommended for the pediatric population (under 18 years) as safety and efficacy have not been established. Use in older adults requires special supervision due to increased risks. Women who are breastfeeding or actively attempting to conceive are advised against use, as classified by regulatory authorities.

Interactions with other medicines and products

Inflacam 0.5% (Piroxicam) interacts with specific medicinal products and substances, resulting in formally documented changes to systemic exposure or pharmacodynamic effects, as described in regulatory documents. The profile is primarily characterized by Pharmacodynamic Risk Reinforcement and Pharmacokinetic Clearance Modification. Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) must be avoided due to the significantly increased risk of gastrointestinal (GI) toxicity and bleeding. The medicine is also formally contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Population-specific interaction notes state that co-administration with ACE Inhibitors or ARBs in elderly or renal impaired patients may result in deterioration of renal function. Furthermore, individuals classified as CYP2C9 Poor Metabolizers may experience abnormally high Piroxicam plasma levels due to documented reduced metabolic clearance. Food causes a delay in the rate of absorption but does not affect the overall extent of exposure.

The active molecule, Piroxicam, modulates physiological activity through two primary biological domains. The core action involves the non-selective inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. This molecular interference restricts the arachidonic acid cascade, significantly reducing the synthesis of chemical mediators, including prostaglandins. This reduction in mediator production alters the physiological processes of nerve sensitization and localized vasodilation . Beyond enzyme inhibition, the drug exerts a stabilizing influence on the lysosomal membranes within inflammatory cells, which results in a restriction of the release of destructive hydrolytic enzymes into the tissue. This effect, alongside a secondary interaction with alpha2-adrenoceptors in the central nervous system, influences activity within peripheral tissue and modulates central nociceptive signaling pathways.

How to Use Inflacam 0.5% — Official Administration Guidelines

This section details the official administration patterns for Piroxicam (Inflacam 0.5%), focusing strictly on usage instructions and dosing limits across its various forms.

Administration Scope

Instruction Classifications

Resulting Procedural Structure

Official step sequence:

• Treatment must adhere to the principle of using the lowest effective dosage for the shortest duration possible.
• The systemic dose must not chronically exceed the 20 mg daily maximum.
• Therapeutic assessment requires waiting approximately two weeks for the full effect, and the need for continued treatment must be formally reviewed within 14 days.

Connection to the overall use protocol (2–4 sentences): The official administration protocol is structured to standardize the delivery method and dosage limits of the medicine across its various forms. This protocol dictates the required intake conditions, such as consuming the systemic dose with food, and sets the mandatory 20 mg daily maximum for sustained use. By integrating specific rules for administration route, timing, and population-based adjustments, the official instructions establish a structured framework for proper usage.

Research Evidence / Overview of Studies for Inflacam 0.5%

Evidence Supporting Chronic Inflammatory Joint Conditions

The research base for Piroxicam, the active ingredient in Inflacam 0.5%, has been built using Randomized Controlled Trials (RCTs) and supporting Systematic Reviews for conditions like osteoarthritis (OA) and rheumatoid arthritis (RA). These studies were applied in research contexts focused on conditions characterized by fluctuating or unstable symptoms typical of these chronic conditions.

For OA and RA, researchers focused on adult populations. Studies monitored outcomes related to physical discomfort, such as patient-reported outcomes describing perceived discomfort, measures of joint stiffness and swelling, and functional ability. Studies report measured changes in outcomes observed during the study period. The volume and type of research available for these chronic uses is often referenced by regulatory bodies when reviewing established research.

Research Base for Acute and Episodic Pain Management

Piroxicam was also evaluated in research contexts focused on conditions characterized by fluctuating or episodic manifestations, including specific research exploring short-term symptom changes in acute musculoskeletal disorders and episodic conditions such as primary dysmenorrhoea (menstrual pain) and acute gouty arthritis flares. Research examined outcomes linked to inflammatory or irritative states, such as acute pain assessments and localized swelling. Studies documented reports of changes in pain severity over the course of treatment.

Evidence is classified as Moderate Level based on the available research and the agent's established profile. The follow-up durations were limited in these trials, often focusing only on the immediate acute phase of the episode.

Research Gaps and Areas of Uncertainty

A consistent limitation across the evidence landscape is that follow-up durations were limited in many of the key efficacy studies, particularly when considering the lifelong nature of chronic conditions like OA and RA. This means long-term effects are not fully established regarding sustained effectiveness. Data for certain groups are limited. The existing studies describe short-term measurements, and the evidence highlights what is known — and what is still uncertain — regarding long-term, sustained outcomes.

Key Studies & References

1. Efficacy and safety of piroxicam revisited: a global meta-analysis of randomised clinical trials

Common questions about Inflacam 0.5% (FAQ)

Q: What is the main use of Inflacam 0.5%?

According to the official product information, Inflacam 0.5% is indicated for the treatment of non-infectious inflammation affecting the anterior segment of the eye. Regulatory documents indicate its function is to manage swelling and irritation in the anterior part of the eye that is not due to a bacterial, fungal, or viral infection. Its use is limited to adults.

Q: What is the active substance in Inflacam 0.5%?

The active substance in Inflacam 0.5% is indometacin. Indometacin is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is used for its anti-inflammatory properties. Official product information states that the strength is 0.5%.

Q: Is Inflacam 0.5% a type of steroid?

No, Inflacam 0.5% is not a steroid. It contains the active substance indometacin, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official information confirms that this is a non-corticosteroid medicine used to manage inflammation.

Q: Can Inflacam 0.5% be used after eye surgery?

The official product information includes the prevention of a condition called miosis (pupil constriction) during cataract surgery as one of its regulatory indications. Its use is also indicated for the management of inflammation that may occur following specific types of surgery. This information is based strictly on studies and official product labeling.

Q: Does Inflacam 0.5% come in a dropper bottle?

According to the official product information, Inflacam 0.5% is provided as eye drops. The regulatory documents confirm that the pharmaceutical form is an eye drop solution. This solution is intended for application to the eye.

How to Store and Dispose of Inflacam 0.5%?

The storage and disposal guidelines for Inflacam 0.5% (Piroxicam solution/suspension) are based strictly on official regulatory labeling to ensure product stability and safety.

Storage Requirements

Official Disposal Rules

Unused or expired Inflacam 0.5% must be handled as pharmaceutical waste and should not be flushed down the toilet or poured down a drain. The preferred method is utilizing a drug take-back program. If a program is unavailable, mix the medicine with an unappealing substance (such as dirt or coffee grounds) and place the mixture into a sealed bag before discarding it in the household trash.